Description
Vidalista ct (Tadalafil) 20 mg
Vidalista ct 20 mg is a chewable tadalafil product. Tadalafil is a prescription phosphodiesterase type 5 (PDE5) inhibitor used for erectile dysfunction in adult men. The chewable form is an oral dosage form of tadalafil; the verified active ingredient is tadalafil.
Active Ingredient and Medicine Class
The verified active ingredient is tadalafil, a PDE5 inhibitor. This medicine class is known for increasing blood flow in the penis during sexual stimulation by supporting the normal nitric oxide–cGMP pathway.
Established Medical Uses
Tadalafil is established for the treatment of erectile dysfunction. In some regulatory products, tadalafil is also approved for benign prostatic hyperplasia and for men with both erectile dysfunction and BPH, but the supplied product description specifically identifies the erectile dysfunction use. Use depends on the local product licence.
How It Works
Tadalafil inhibits PDE5, an enzyme that breaks down cyclic GMP in smooth muscle tissue. By slowing this breakdown, it helps relax penile blood vessels during sexual arousal, which can improve the ability to achieve and maintain an erection.
Important Safety Information
Tadalafil must not be used with organic nitrates, because the combination can cause a dangerous fall in blood pressure. It is also contraindicated in people with a serious hypersensitivity reaction to tadalafil or any tablet component. Important precautions include cardiovascular disease where sexual activity may be unsafe, a tendency to low blood pressure, and conditions that increase the risk of prolonged erection.
Clinically significant interactions are reported with alpha-blockers, antihypertensives, riociguat and substantial amounts of alcohol, all of which may increase the risk of hypotension. CYP3A4 inhibitors can also increase tadalafil exposure.
Possible Side Effects
Commonly reported adverse effects include headache, dyspepsia, back pain, myalgia, nasal congestion, flushing and dizziness. Less common but serious reactions can include priapism, sudden visual loss, sudden hearing loss, and symptomatic low blood pressure.
Scientific Evidence
Clinical reviews and meta-analyses indexed in PubMed support tadalafil as an effective oral PDE5 inhibitor for erectile dysfunction, with benefits seen across different severities and causes of the condition. Reviews also note its relatively long duration of action compared with some other PDE5 inhibitors. Reported adverse effects in trials were generally consistent with the class profile.
Medical Information Notice
This page is an educational summary based on sources available at the time of review and does not replace the official patient leaflet or assessment by a qualified healthcare professional.
Medical Sources
- DailyMed / U.S. FDA: CHEWTADZY (tadalafil) chewable tablets, prescribing information. View source
- Eric J H Meuleman, “Review of tadalafil in the treatment of erectile dysfunction,” Expert Opinion on Pharmacotherapy, 2003. View PubMed article
